Audience

Read by all 50 of the biggest Pharma companies, like Pfizer and Novartis, as well as thousands of innovative, clinical-stage biotechs.

OUR PLATFORMS draw

252k+
daily email subscribers
700K+
unique monthly visitors
1.8M
average monthly page views
70K+
event registrations

OUR SUBSCRIBERS count

OUR SUBSCRIBERS span

OUR TOP STORIES include

Sarepta CEO Doug Ingram to step down, ending controversial tenure at Duchenne biotech
February 25, 2026
FDA probes internal Prasad complaints with outside help
February 26, 2026
OrbiMed jumps to number one on the top 100 list of biotech venture investors
February 26, 2026
The Broad wins another — perhaps final — battle in the war over Feng Zhang's CRISPR patents
September 10, 2018
Sanofi’s rare disease drug notches one win, one loss in a pair of Phase 3 trials
February 2, 2026

Get started

Connect with us to request a media kit and learn more about rates and availability.

Julie O'Meara
Julie O'Meara
Executive Director, Brand Partnerships, Endpoints News
Melissa Nazzaro